# Phase Ⅱ/Ⅲ Clinical Study of Tumor Treating Fields （EFE-P100）Combined With Docetaxel in the Treatment of Stage IV Non-small Cell Lung Cancer Patients With Disease Progression After Platinum-based Chemotherapy and Anti-programmed Death 1（PD-1)/Programmed Cell Death-Ligand 1(PD-L1) Antibody Treatment

> **NCT05661240** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Jiangsu Healthy Life Innovation Medical Technology Co., Ltd** · enrollment: 348 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer (NSCLC)

## Interventions

- **DEVICE:** Tumor treating fields（EFE-P100）
- **DRUG:** Docetaxel injection

## Key facts

- **NCT ID:** NCT05661240
- **Lead sponsor:** Jiangsu Healthy Life Innovation Medical Technology Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-12-20
- **Primary completion:** 2024-05-25
- **Final completion:** 2025-07-31
- **Target enrollment:** 348 (ESTIMATED)
- **Last updated:** 2022-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05661240

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05661240, "Phase Ⅱ/Ⅲ Clinical Study of Tumor Treating Fields （EFE-P100）Combined With Docetaxel in the Treatment of Stage IV Non-small Cell Lung Cancer Patients With Disease Progression After Platinum-based Chemotherapy and Anti-programmed Death 1（PD-1)/Programmed Cell Death-Ligand 1(PD-L1) Antibody Treatment". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05661240. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*